Abstract
Importance
Compares the responses of four AI models to common nephrology-related questions encountered in clinical settings.
Objective
To evaluate generative AI models in enhancing nephrology patient communication and education.
Design
Generative AI in Nephrology
Setting
In a study conducted from December 8–12, 2023, and October 21–23, 2024, IT engineers evaluated GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 for nephrology patient communication and education, querying each with 21 nephrology questions and three renal biopsy reports, repeated for consistency.
Intervention(s) (for clinical trials) or Exposure(s) (for observational studies)
None.
Main Outcome(s) and Measure(s)
Fifteen nephrologists and one nephrology researcher assessed responses for Appropriateness, Helpfulness, Consistency, and human-like empathy, with rating scale (1–4). Using Shapiro–Wilk and Mann–Whitney U tests with Holm correction, along with TF-IDF, BertScore, and ROUGE were used. The study compared the performance of GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 across 24 nephrology-related questions.
Results
GPT-4o consistently achieved high scores in Appropriateness (3.39 ± 0.7) and Helpfulness (3.24 ± 0.73), while PaLM 2 demonstrated the highest consistency score (3.0 ± 0.86). In empathy, GPT-4 achieved the highest overall score (80.73%), excelling in patient-centric scenarios, followed by GPT-4o (76.56%). PaLM 2 showed competitive empathy in specific cases, despite scoring lower in consistency and Appropriateness.
For Kidney-Related Queries, GPT-4o excelled in relevance metrics, achieving the highest BertScore (0.57) and ROUGE for one-word metrics (0.54). Gemini 1.0 Ultra led in generating coherent responses for Renal Biopsy Reports with the highest TF-IDF (0.56) and ROUGE for longest similar sentences (0.47). All 101 references provided by GPT-4 were 100% accurate.
Conclusions and Relevance
GPT-4o emerged as the most accurate and consistent model across most evaluation categories, while GPT-4 demonstrated superior empathy and balanced performance. PaLM 2 and Gemini 1.0 Ultra showed strengths in specific areas, highlighting the potential for tailored applications of generative AI in nephrology clinical practice.
Key points
Question: Many have expressed confusion about the information on these pre-End Stage Kidney Disease (pre-ESKD) program, struggling to understand it due to the rigid and generic presentation, which does not address individual needs effectively. Findings: Generative AI models like GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 demonstrate potential in aiding clinical renal services by providing appropriate and empathetic responses to patient questions. Meaning: Exploration of utilizing LLMs in clinical renal practice holds great potential and importance.
Introduction
Taiwan is globally recognized for its advancements in digital innovation, with a report at the start of 2023 indicating that there were 21.68 million internet users in the country, translating to an impressive internet penetration rate of 90.7%. 1 Despite this digital prowess and the abundant availability of health-related information online, a significant challenge persists for the general public and patients in terms of interpreting this data.2–5 This difficulty often stems from limited medical knowledge, leading to confusion and potentially misleading conclusions. 6 While many hospitals offer health education on their websites, the content is often too technical for the general public to easily understand. Additionally, the Taiwan National Health Insurance Administration launched the pre-end stage kidney disease (pre-ESKD) program in November 2006, specifically targeting high-risk individuals at stages 3B-5 of chronic kidney disease (CKD). This initiative, along with increased government efforts to educate the public about the symptoms of kidney damage, has raised awareness. However, this issue is particularly noticeable in our clinical practice with renal patients. Many have expressed confusion about the information on these websites struggling to understand it due to the rigid and generic presentation, which does not address individual needs effectively.7,8
Thus, in response to this information gap, the advent of Generative AI technology in early 2022 offers a promising solution. 9 This technology claims to provide tailored answers and mimic diverse roles based on user inputs, potentially bridging the gap between complex medical information and patient comprehension in a manner that is both accessible and personalized to individual needs. 10 The integration of LLMs in nephrology shows both potential and limitations across clinical decision support, patient education, and administrative tasks. A 2023 study on ChatGPT's performance in nephrology test questions revealed variability in accuracy and consistency, indicating the need for further validation. 11 A systematic review by Unger et al. highlighted LLMs’ potential in streamlining workflows, predicting disease progression, interpreting laboratory data, managing renal diets, and enhancing patient education. 12 For instance, GPT-4 demonstrated a 90–94% accuracy in managing continuous renal replacement therapy alarms, thereby reducing ICU alarm fatigue. 12 In another study, Miao et al. addressed challenges like hallucinations—where LLMs produce incorrect or irrelevant outputs—by integrating Retrieval-Augmented Generation (RAG) strategies. They customized a ChatGPT model aligned with the KDIGO 2023 guidelines for CKD, showcasing its potential in providing specialized, accurate medical advice. 13 Pham et al. evaluated ChatGPT-4's accuracy in triaging nephrology patient messages, finding a 93% correctness rate. This underscores AI's potential to enhance operational efficiency and patient care in outpatient clinics. 14 However, a comparative study by Wu et al. revealed that while GPT-4 answered 73.3% of nephrology multiple-choice questions correctly, open-source LLMs like Koala 7B and Falcon 7B lagged, with correctness rates between 17.1% and 25.5%. This indicates that not all LLMs are equally adept in specialized medical domains. 15 Collectively, these studies illustrate the promising applications of LLMs in nephrology, while also emphasizing the need for continuous evaluation and customization to ensure accuracy and reliability in clinical settings.
Therefore, we conducted a study to evaluate the effectiveness of Generative AI as a supportive tool for medical inquiries related to nephrology, particularly in the context of increasing outpatient visits in Taiwan. This study examines whether AI can enhance patient communication and education by assisting medical professionals in responding to common nephrology-related questions encountered in clinical settings.
The study compares the responses of four AI models—GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2—in terms of their ability to provide accurate, understandable, and empathetic explanations. Additionally, we assess the capability of these AI systems to interpret and explain renal biopsy reports to patients and their families, covering three distinct types of biopsy results.
This research is designed with the primary goal of supporting individual physicians by helping them bridge communication gaps with patients. However, if the study demonstrates promising results, it could also inform institutional applications, such as hospital-wide AI integration in nephrology outpatient clinics and dialysis centers. In such settings, AI could assist in standardizing patient education, improving workflow efficiency, and supplementing physician–patient interactions, ultimately enhancing the quality of care on a larger scale.
Methods
The study included 15 nephrologists and one nephrology researcher, with participants representing a diverse range of healthcare facilities, from dialysis-focused primary care clinics to medical centers across northern, central, and southern Taiwan. Institutions involved were Taipei Medical University Hospital, Keelung Chang Gung Memorial Hospital, China Medical University Hospital, Asia University Hospital, Kaohsiung Chang Gung Memorial Hospital, and Hongde Clinic. The 15 nephrologists had received their nephrology fellowship training at various major medical centers, including National Taiwan University Hospital, Tri-Service General Hospital, Taipei Veterans General Hospital, China Medical University Hospital, Linkou Chang Gung Memorial Hospital, and Kaohsiung Chang Gung Memorial Hospital. The current study explored the potential of integrating AI platforms, specifically GPT-4 and GPT-4o (OpenAI), PaLM 2 (accessed via Google Bard), and Gemini 1.0 Ultra (Google). It is important to note that Bard is a conversational AI service developed by Google and not a model itself. While Bard was initially powered by LaMDA, it was updated in May 2023 to use PaLM 2 as its underlying model. Therefore, the responses generated via Bard in this study reflect the performance of PaLM 2. At the time of our evaluation (December 2023), Bard was confirmed to be operating on the PaLM 2 model, based on official statements from Google. All models were accessed through their respective official graphical user interfaces (GUIs), simulating typical end-user interactions. No APIs or automated scripts were used. Specifically, Gemini 1.0 Ultra was accessed via the official Gemini service interface provided by Google.”
A total of 21 nephrology-related questions and 3 renal biopsy reports were curated by experienced nephrologists to reflect common inquiries in nephrology services. The study comprised 21 questions, divided into three distinct categories: 7 questions focusing on dialysis-related issues (Q1–Q7), 7 questions addressing kidney examinations (Q8–Q14), and another 7 pertaining to general kidney-related issues (Q15–Q21). Additionally, the results of three renal biopsy reports were analyzed, revealing diagnoses of IgA nephropathy, focal segmental glomerulosclerosis, and membranous nephropathy, in that order (Q22–Q24) (Table 1 and Appendix 1).
Comprehensive performance evaluation of ai models (GPT-4, Gemini 1.0 Ultra, PaLM 2, GPT-4o) on kidney health and reports.
The renal biopsy reports presented in this study were constructed using fictitious data. These reports were created based on templates from our institution, ensuring they reflected realistic clinical scenarios. Our study recorded all responses generated by GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 without applying any filtering criteria. Every response was documented as output by the AI models to ensure an unbiased evaluation of their performance. This approach allows for a comprehensive analysis of the accuracy, consistency, and Appropriateness of AI-generated responses in nephrology-related inquiries.
The nephrologist team comprised 15 nephrologists and nephrology researcher, each with extensive experience in clinical nephrology care, had practice durations ranging from 5 to more than 20 years.
Data collection
From December 8, 2023, to December 12, 2023, GPT-4, Gemini 1.0 Ultra, and PaLM 2 were used for evaluation. Additionally, from October 21, 2024, to October 23, 2024, GPT-4o was assessed. During these periods, a team of IT engineers queried the AI models using a predetermined set of nephrology-related questions and renal biopsy reports. Each question and report were entered individually and repeated three times consecutively to evaluate the consistency of the responses. The outputs from GPT-4, Gemini 1.0 Ultra, PaLM 2, and GPT-4o for all 21 questions and 3 biopsy reports were then compiled, anonymized, and prepared for further evaluation.
To provide an objective evaluation, we employed analytical tools inclusive of Term Frequency-Inverse Document Frequency (TF-IDF), 16 BertScore, 16 and ROUGE (Recall-Oriented Understudy for Gisting Evaluation) for 1-word, 2-word, and longest similar sentence scores, 17 which were utilized to compare the performance of the four language models – GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 – in terms of consistency across four categories pertaining to renal issues and examinations.
After evaluating four AI models on Appropriateness, Helpfulness, and Human-Like Empathy, the model with the highest overall ratings was identified as the top performer. This model was then asked to provide references for each question posed during the evaluation.
Evaluation process
An interactive website was developed to present these responses in a questionnaire format. Fifteen nephrologists and one nephrology researcher, blinded to the origin of the responses, were tasked to evaluate them. They rated each response based on Appropriateness, Helpfulness, and Consistency using a 4-point scale (1 indicating the least and 4 the highest score). Helpfulness measures how much a tool aids clinicians in tasks like diagnosis and treatment planning, leading to efficiency and improved accuracy. Consistency ensures reliable performance across different scenarios, enhancing clinical reliability and reducing the need for repeated checks. Appropriateness assesses whether the tool suits the specific clinical context and patient population, ensuring relevance and precision in decision-making. Additionally, they evaluated human-like empathy through a binary categorization method, labeling each response as either demonstrating no human-like empathy or showcasing human-like empathy. The evaluation criteria and categories were directly based on a precedent study which assessed the performance of GPT-4 in providing patient information in the context of PET/CT imaging. 18 From November 5, 2024, to November 10, 2024, an IT engineer was responsible for verifying the accuracy of the references provided by the top-performing generative AI model. The verification focused solely on the existence of these sources, without assessing if the content of the references directly correlated with the responses and questions posed.
Blinding and anonymity
The study was conducted in a double-blind manner. The IT engineers could not identify the nephrologists participating in the study, as the nephrologists used code names for their website interactions. Additionally, the nephrologists were unaware of their colleagues’ participation and could not access each other's ratings. They were also blinded to the source of the responses, not knowing whether a response came from GPT-4, Gemini 1.0 Ultra, PaLM 2, and GPT-4o.
Data analysis
Each question and report were individually inputted and queried three times across three AI platforms: GPT-4, Gemini 1.0 Ultra, PaLM 2, and GPT-4o. This process resulted in a total of 288 responses generated by GPT-4, Gemini 1.0 Ultra, PaLM 2, and GPT-4o. Subsequently, these responses were evaluated based on four criteria: Appropriateness, Helpfulness, Consistency, and Human-Like Empathy.
The IT engineers collected and analyzed the data, calculating the final results and relevant statistics. For the evaluation of Appropriateness, Helpfulness, and Consistency, we calculated the mean and standard deviation for each parameter. In the case of Human-Like Empathy, a categorical variable, we determined the percentage distribution. Additionally, we assigned a scoring system for Human-Like Empathy: “no human-like empathy” was allocated zero points, and “human-like empathy” was assigned one point. The average of these scores was also computed. Statistical analyses were conducted to assess differences in model performance across evaluation dimensions. The Shapiro–Wilk test was first applied to evaluate whether the data followed a normal distribution. Since the data did not meet the assumption of normality, the Kruskal–Wallis H test, a non-parametric method, was employed to determine whether there were significant differences in scores across the models. For questions showing significant differences in the Kruskal–Wallis H test, pairwise comparisons between models were performed using the Mann–Whitney U test. To address the risk of Type I error due to multiple comparisons, Holm's correction was applied to adjust the p-values. Holm's method was chosen as it provides a more flexible approach than Bonferroni correction, maintaining greater statistical power while effectively controlling the family-wise error rate. This analysis framework ensured the robust identification of significant differences while minimizing the risk of false positives. A p-value of less than 0.05 was considered statistically significant.
TF-IDF calculates the importance of a word in a document, with Term Frequency (TF) counting the occurrences of a word, normalized by the document's length, and Inverse Document Frequency (IDF) assessing the rarity of the word across all documents using a logarithmic scale. The TF-IDF score is then obtained by multiplying TF with IDF. BertScore measures the similarity between the generated responses and a reference text by computing the cosine similarity of their word embeddings, with the final score being the average of these similarities. For ROUGE, which is used for evaluating summaries or translations, we applied ROUGE-1 and ROUGE-2 to measure the overlap of single- and two-word phrases, respectively, between the AI text and reference texts, while ROUGE-L assesses the longest matching sequence of words. These methods employ a scale ranging from 0 to 1, where 0 indicates no similarity and 1 represents identical or maximum similarity.
Ethical considerations
This study did not involve human participants or patient data. The evaluation was conducted using standardized nephrology-related questions and renal biopsy reports. Additionally, all biopsy reports were fully de-identified, and the study received Institutional Review Board (IRB) approval under CMUH108-REC2-167, confirming that ethical considerations were addressed appropriately.
The study has been reported in line with the STROCSS criteria. 16
Results
Table 2 presents the evaluation results from 15 nephrologists and one nephrology researcher, comparing the outputs of GPT-4, Gemini 1.0 Ultra, PaLM 2, and GPT-4o across all 21 questions and the three renal biopsy reports. Regarding the overall performance in Appropriateness, the average scores (Mean ± SD) were as follows: GPT-4 scored 3.18 ± 0.86, GPT-4o scored 3.39 ± 0.7, Gemini 1.0 Ultra 3.02 ± 0.95, and PaLM 2 3.09 ± 0.92. In terms of Helpfulness, the respective average scores were 3.1 ± 0.87 for GPT-4, 3.24 ± 0.73 for GPT-4o, 2.98 ± 0.92 for Gemini 1.0 Ultra, and 3.01 ± 0.9 for PaLM 2. Finally, assessing Consistency across the four models for each question, the average scores were 1.62 ± 0.85 for GPT-4, 1.5 ± 0.82 for GPT-4o, 1.53 ± 0.83 for Gemini 1.0 Ultra, and 3.0 ± 0.86 for PaLM 2. These results demonstrate nuanced differences in the performance of each AI model across the evaluated criteria. The results showed GPT-4o displayed relatively consistent scores in all categories. Gemini 1.0 Ultra showed a comparable level of performance, with scores slightly lower than GPT-4o but more uniform across different categories. In contrast, PaLM 2 achieved a significantly higher average score of 3.0 ± 0.86, suggesting a notable difference in performance of consistency compared to the other models.
Comparative analysis of AI models across different categories.
Table 3 showed further analysis of the performance of four generative AI models across three categories. In the category of Dialysis-Related Issues (Q1–Q7), the performance was assessed based on Appropriateness, Helpfulness, and Consistency. GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 scored an average of 3.32 ± 0.80, 3.33 ± 0.78, 3.00 ± 0.96, and 3.09 ± 0.96, respectively, in Appropriateness. For Helpfulness, the scores were highest with 3.22 ± 0.87 for GPT-4. In terms of Consistency, the PaLM 2 models scored highest with 3.07 ± 0.86.
Comparative performance of AI models on kidney-related queries.
Performance metrics are presented as average scores (Avg) with standard deviations (SD) for three categories: Appropriateness, Helpfulness, and Consistency.
In the Kidney Examinations category (Q8–Q14), GPT-4o achieved a score of 3.39 ± 0.66 in Appropriateness, and also outperformed the others in Helpfulness with a score of 3.29 ± 0.69. PaLM 2 led in Consistency, scoring 3.04 ± 0.81.
For Kidney-Related Queries (Q15–Q21), GPT-4o registered the highest score in Appropriateness (3.44 ± 0.69) and Helpfulness (3.28 ± 0.73). In Consistency, PaLM 2 led with a score of 2.93 ± 0.87. In Biopsy-Related Issues, GPT-4o scoring 3.39 ± 0.66 in Appropriateness, 3.19 ± 0.67 in Helpfulness, and Gemini 1.0 Ultra 2.92 ± 0.95 in Consistency.
Table 4 presents the Shapiro–Wilk test results for assessing the normality of score distributions across three evaluation categories—Appropriateness, Helpfulness, and Inconsistency—for each question (Q1–Q24) and each language model (GPT-4, GPT-4o, Gemini 1.0 Ultra, PaLM 2). For the Appropriateness assessment, GPT-4 demonstrated normal or near-normal distribution in eight questions (Q6, Q7, Q8, Q13, Q17, Q22, Q23, and Q24), with the highest p-value observed for Q22 (p = 0.828), indicating the closest fit to a normal distribution. GPT-4o, by contrast, showed normal or near-normal distribution in only two questions (Q1 and Q19), suggesting a limited alignment with normality for its data. Gemini 1.0 Ultra exhibited normal or near-normal distributions in 10 questions (Q3, Q6, Q7, Q8, Q10, Q12, Q13, Q19, Q23, and Q24), while PaLM 2 achieved normal or near-normal distributions in nine questions (Q2, Q5, Q9, Q10, Q12, Q16, Q19, Q22, and Q23), with notable consistency in Q16 and Q22.
Shapiro–Wilk normality test results for Appropriateness, Helpfulness, and Inconsistency evaluations across different LLM models (GPT-4, GPT-4o, Gemini 1.0 Ultra, PaLM 2) for each question.
For the Helpfulness evaluation, GPT-4 exhibited normal or near-normal distributions in 10 questions (Q6, Q7, Q10, Q13, Q15, Q16, Q17, Q22, Q23, and Q24). GPT-4o displayed normality in seven questions (Q1, Q7, Q8, Q11, Q13, Q16, and Q19). Gemini 1.0 Ultra outperformed in this category, with 13 questions showing normal or near-normal distributions (Q3, Q6, Q8, Q10, Q11, Q12, Q13, Q17, Q18, Q19, Q21, Q23, and Q24), with the highest p-value for Q8 (p = 0.602). PaLM 2 exhibited the strongest performance, with 15 questions achieving normal or near-normal distributions (Q2, Q3, Q5, Q7, Q8, Q10, Q11, Q13, Q15, Q16, Q17, Q18, Q22, Q23, and Q24).
In contrast, the Inconsistency evaluation revealed significant deviations from normality across all models, with only a few questions approaching normal distributions. However, none met the assumptions of a standard normal distribution. These findings suggest that inconsistency scores are heavily influenced by variations in response consistency across models, resulting in strongly asymmetric or anomalous distribution patterns.
Table 5 demonstrated the results of performance of generative AIs in empathy. The comparative analysis of human-like empathy demonstrated by responses from GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 across 24 questions revealed notable variations in performance among the models. On average, GPT-4 achieved the highest empathy score (80.73%), followed by GPT-4o (76.56%), PaLM 2 (75.96%), and Gemini 1.0 Ultra (68.58%). GPT-4 consistently outperformed other models in most questions, with standout performances in Q2 (95.83%), Q16 (89.58%), and Q24 (87.50%), reflecting its strong ability to generate empathetic responses across various scenarios.
Comparative analysis of human-like empathy demonstration in responses by AI models across 24 questions.
GPT-4o demonstrated robust performance in questions such as Q13 (85.42%) and Q21 (87.50%), where it surpassed GPT-4 in demonstrating empathy. PaLM 2 also showed competitive performance, excelling in Q4 (91.67%) and Q15 (87.50%), highlighting its capability to match or even exceed GPT-4 in specific contexts. However, Gemini lagged behind in overall empathy, particularly in questions like Q5 (47.92%) and Q6 (47.92%), where its scores were significantly lower compared to the other models.
Despite these variations, all models showed comparable performance in certain questions, such as Q8 and Q24, where empathy scores were closely aligned across models. This indicates that while some generative AI models consistently excel in demonstrating empathy, the context and nature of the questions also play a significant role in their relative performance. Overall, GPT-4 emerged as the most consistent and empathetic model, while GPT-4o and PaLM 2 showed specific strengths, and Gemini 1.0 Ultra demonstrated room for improvement in empathetic communication.
The Kruskal–Wallis test was used to evaluate the performance of the four large language models (LLPs; GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2) across three evaluation categories: Appropriateness, Helpfulness, and Inconsistency, measured across multiple questions (Q1–Q24) (Table 6). In the Appropriateness category, GPT-4o consistently demonstrated higher mean ranks across most questions, with notable performance in Q20 (mean rank 3.667) and Q21 (mean rank 3.646). PaLM 2 also showed competitive results, particularly in Q21 (mean rank 3.333). GPT-4 and Gemini 1.0 Ultra achieved moderate performance in this category, with occasional peaks, such as Q10 for GPT-4 (mean rank 3.271) and Q13 for Gemini 1.0 Ultra (mean rank 3.271). For Helpfulness, GPT-4o again displayed strong results, leading in questions such as Q18 (mean rank 3.521) and Q20 (mean rank 3.396). PaLM 2 performed consistently across the questions, with mean ranks generally above 3.0. Gemini 1.0 Ultra and GPT-4 ranked similarly, with comparable performance in questions like Q10 and Q13. In the Inconsistency category, PaLM 2 had the highest scores in several questions, reflecting less variability in its outputs, as seen in Q1 (mean rank 3.25) and Q21 (mean rank 3.25). GPT-4o demonstrated lower ranks for inconsistency, with standout performance in Q2 (mean rank 1.188) and Q16 (mean rank 1.188), indicating fewer inconsistencies. GPT-4 and Gemini 1.0 Ultra showed moderate inconsistency rankings, often lower than PaLM 2 but higher than GPT-4o.
Kruskal–Wallis test mean ranks for different LLM models (GPT-4, GPT-4o, Gemini 1.0 Ultra, PaLM 2) performance across evaluation categories.
Table 7 provides the Kruskal–Wallis test results, comparing the performance of four language models (GPT-4, GPT-4.0, Gemini 1.0 Ultra, PaLM 2) across different evaluation criteria (Appropriateness, Helpfulness, Inconsistency). The evaluation covers each question (Q1–Q24) to assess performance differences across models for these questions.
Kruskal–Wallis test results for model comparisons across different evaluation criteria (appropriate, helpful, inconsistent).
Df: degrees of freedom; Asymp Sig: asymptotic significance (p-value).
* p < 0.05.
** p < 0.001.
The Kruskal–Wallis H test revealed significant differences among the models in specific evaluation dimensions. For Appropriateness, significant differences were observed in questions Q2 (H = 9.85, p = 0.0199) and Q18 (H = 8.06, p = 0.0447), whereas the Helpfulness dimension showed no significant differences across all questions, with p-values exceeding 0.05. In contrast, the Inconsistency dimension revealed significant differences for most questions (p < 0.05), except for Q19. Post-hoc analysis using the Mann–Whitney U test with Holm correction further explored these differences. In the Appropriateness dimension, the significant differences in Q2 and Q18 identified in the Kruskal–Wallis test were not retained after correction, suggesting the differences among models were not statistically robust. For the Inconsistency dimension, GPT-4, GPT-4o, and Gemini 1.0 Ultra demonstrated similar patterns in their responses for most questions, whereas PaLM 2 consistently exhibited significant differences compared to the other models, particularly in questions 1–18, 20, 21, and 24, even after Holm correction. However, no significant differences were observed between GPT-4 and GPT-4o, or between GPT-4o and Gemini 1.0 Ultra, in most questions, and any initially significant results, such as for Q11, lost significance after correction. In contrast, PaLM 2 displayed significant differences compared to the other models across most questions, except for Q19, highlighting its distinct response patterns. Overall, while the differences among models were limited in the Appropriateness and Helpfulness dimensions, the Inconsistency dimension revealed substantial distinctions, with PaLM 2 showing notably divergent behavior compared to GPT-4, GPT-4o, and Gemini 1.0 Ultra. This underscores the unique response patterns exhibited by PaLM 2 in comparison to its counterparts.
Table 8 showed the comparative analysis of language models for kidney-related content. The comparative analysis of language models (GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2) across four kidney-related content categories—Dialysis-Related Issues (Q1–Q7), Kidney Examinations (Q8–Q14), Kidney-Related Queries (Q15–Q21), and Renal Biopsy Reports (Q22–Q24)—revealed distinct performance patterns. For Dialysis-Related Issues, GPT-4o achieved the highest BertScore (0.54 ± 0.02) and ROUGE (one word) score (0.50 ± 0.02), while PaLM 2 led in TF-IDF (0.54 ± 0.10) and ROUGE (longest similar sentences) score (0.38 ± 0.09). Notably, Gemini 1.0 Ultra showed competitive ROUGE (two words) performance (0.28 ± 0.11), highlighting its strength in multi-word content generation. In the Kidney Examinations category, PaLM 2 exhibited the highest TF-IDF (0.60 ± 0.12) and strong ROUGE (longest similar sentences) performance (0.36 ± 0.03), while GPT-4o maintained superiority in BertScore (0.54 ± 0.03) and ROUGE (one word) (0.49 ± 0.03). Gemini 1.0 Ultra's performance in this category was more variable, showing lower scores in ROUGE (one word) and ROUGE (two words), but its TF-IDF (0.49 ± 0.10) was comparable to GPT-4 and GPT-4o. For Kidney-Related Queries, GPT-4o again demonstrated strong performance, achieving the highest BertScore (0.57 ± 0.06) and ROUGE (one word) (0.54 ± 0.06), while PaLM 2 performed well in ROUGE (two words) (0.31 ± 0.05). GPT-4 displayed consistent performance across all metrics, particularly in ROUGE (one word) (0.54 ± 0.08). Gemini 1.0 Ultra exhibited moderate performance, with slightly lower scores in multi-word ROUGE metrics. In the Renal Biopsy Reports category, Gemini Pro stood out with the highest scores in TF-IDF (0.56 ± 0.13), ROUGE (longest similar sentences) (0.47 ± 0.10), and ROUGE (two words) (0.38 ± 0.14), reflecting its ability to generate coherent and contextually relevant outputs for complex content. GPT-4 and GPT-4o performed consistently in ROUGE (one word) and BertScore metrics, with GPT-4o achieving a BertScore of 0.46 ± 0.05. PaLM 2, however, showed the weakest performance in this category, with lower scores across most metrics, particularly in ROUGE (longest similar sentences) (0.15 ± 0.02).
Comparative analysis of language models in kidney-related content.
Overall, GPT-4o consistently demonstrated high accuracy and relevance across most categories, particularly excelling in single-word metrics, while PaLM 2 showed strength in multi-word and TF-IDF metrics for certain content types. Gemini 1.0 Ultra's performance was variable but excelled in generating contextually rich outputs for renal biopsy-related tasks. GPT-4 provided balanced and reliable results across categories, maintaining competitive scores throughout.
Regarding the accuracy of references provided by GPT-4 across 24 questions, a total of 131 references were initially given. After removing 30 duplicates, the final count stood at 101 unique references. These comprised 4 from books, 86 from medical and clinical journals, and 11 from websites. Upon manual verification, it was confirmed that all 101 references were valid and existing, resulting in a 100% accuracy rate for the references provided by GPT-4. Responses by GPT-4, as well as responses by Gemini 1.0 Ultra, PaLM 2, and GPT-4o were included in Appendices 1, 2, 3, and 4. Detailed references provided by GPT-4 along with website linkages were in Appendix 5.
Discussion
This is the first study to involve sixteen nephrologists and nephrology researchers, each with over five years of experience, from nephrology clinics to medical centers across Taiwan, to evaluate the feasibility of incorporating generative AI in clinical renal settings. Notably, as Gemini 1.0 Ultra and PaLM 2 have since been merged into a single platform, this study uniquely captures and compares the distinct characteristics of these generative AI tools prior to their combination, enabling a meaningful discussion of their differential capabilities and applications.
GPT-4o demonstrated relatively higher performance scores in the categories of Helpfulness and Appropriateness, though it showed lower scores in consistency, suggesting that the model's output remained stable across different contexts. These metrics—Helpfulness, Consistency, and Appropriateness—are crucial in clinical practice as they directly impact time efficiency and accuracy. High scores in these areas can streamline workflows, reduce redundancies, and enhance diagnostic and treatment precision. In this study, we evaluated GPT-4o across various domains of nephrology clinical services, including Dialysis-Related Issues (Q1–Q7), Kidney Examinations (Q8–Q14), Kidney-Related Queries (Q15–Q21), and Renal Biopsy Report Interpretation (Q22–Q24). GPT-4o consistently outperformed other models in subjective assessments by nephrologists, highlighting its potential and advantage as a decision-support tool in clinical renal settings. When integrated into an electronic health record (EHR) system, 19 GPT-4o could provide timely, maybe more evidence-based recommendations and saving time. This preliminary study aims to develop a communication tool designed to facilitate more efficient and effective interactions between clinicians and patients. The goal is to save time while delivering information in a manner that aligns with what clinicians intend to convey, ensuring it is easily understood by patients. The results of our study appear promising, suggesting that the tool could be helpful in achieving these objectives. However, further research focusing on real-world implementation and practical application is necessary to validate these findings and assess its impact in clinical settings.
Human-like empathy, a crucial metric in healthcare, plays a significant role in enhancing patient satisfaction by fostering a sense of being understood. While empathy may not directly save time, it minimizes the need for prolonged face-to-face interactions to address patient concerns, thereby contributing to more efficient and satisfactory clinical encounters. LLMs, particularly ChatGPT, have demonstrated the ability to exhibit human-like empathy in healthcare settings, a finding that aligns with our study results.20,21 Qian et al. have proposed methods to further enhance empathetic responses in these models, while Elyoseph et al. highlighted ChatGPT's superior emotional awareness compared to humans, showcasing its ability to effectively understand and conceptualize emotions.20,22 Considering that training clinicians to demonstrate human-like empathy is time-intensive and can be limited by individual personality traits, 21 the observed empathy scores of at least 76% for GPT and GPT-4o in our study suggest that generative AI could serve as a valuable tool for providing empathetic responses to clinical renal questions. This capability has the potential to augment patient interactions in nephrology, improving communication and fostering trust between clinicians and patients.
Our study demonstrated no significant differences in response patterns between GPT-4, GPT-4o, and Gemini 1.0 Ultra for most questions. However, critical distinctions arise in their data sourcing and internet access. PaLM 2 AI, integrated into Gemini Pro, leverages Google's extensive search network to provide real-time internet connectivity, allowing it to deliver up-to-date insights on current events and topics. 23 This real-time access offers a significant advantage for PaLM 2 AI and Gemini 1.0 Ultra. In contrast, GPT-4 operate without direct internet connectivity, relying on datasets updated only until 2021 in our study while GPT-4o would update information timely. 24 Consequently, their responses may not include the most recent information, which is a notable limitation for addressing current topics. In the context of our renal clinical study, where queries and renal biopsy results did not involve novel exams or treatments, GPT-4, GPT-4o, and Gemini 1.0 Ultra exhibited comparable performance levels, while PaLM 2's performance was significantly lower. Although PaLM 2 is now integrated into Gemini 1.0 Ultra, our findings highlight the importance of pre-evaluating the performance of LLMs across various aspects before incorporating them into clinical settings.
We further contextualized by the question categories to provide a comprehensive evaluation of generative AI model performance in clinical nephrology scenarios. The normality results highlight key differences in the models’ abilities to produce consistent distributions of scores across evaluation categories—Appropriateness, Helpfulness, and Inconsistency. For Appropriateness, GPT-4 demonstrated near-normal distributions across questions addressing dialysis-related issues (e.g. Q6), kidney examinations (e.g. Q8 and Q13), and renal biopsy reports (e.g. Q22–Q24). In contrast, Gemini 1.0 Ultra performed well across multiple categories but had stronger coverage in kidney examination-related questions (e.g. Q3, Q8, and Q12). PaLM 2 achieved normality in questions like Q16 and Q22, showing strengths in kidney-related queries and biopsy discussions. These results suggest a nuanced distribution of strengths among models, with GPT-4 generally excelling in breadth and PaLM 2 showing situational performance advantages. In the Helpfulness evaluation, Gemini 1.0 Ultra outperformed other models, achieving near-normal distributions in kidney examinations and dietary or medication-related queries (e.g. Q6, Q10, Q18). PaLM 2 exhibited the strongest overall performance, particularly in dialysis-related questions such as Q2 and Q7, as well as in patient-facing issues like diet (Q5) and kidney symptom interpretations (Q15). GPT-4 also excelled, particularly in providing recommendations across a range of topics, but GPT-4o lagged, reflecting less consistency in its ability to align responses with clinical expectations. Empathy scores further illuminated these findings. GPT-4 consistently demonstrated the highest empathy levels, excelling in patient-facing questions such as the implications of symptoms (Q16) and post-biopsy care (Q24). PaLM 2 showed competitive empathy in dietary and symptom-related questions (e.g. Q5 and Q15), while GPT-4o had standout performances in specialized areas, such as the evaluation of CKD (e.g. Q19). However, Gemini 1.0 Ultra lagged in empathy, particularly in addressing patient fears and practical concerns (e.g. Q5 and Q6), highlighting an area for model improvement. These findings underline the need for tailored applications of generative AI models in clinical settings. While GPT-4 consistently performs well across categories, PaLM 2 and GPT-4o demonstrate contextual strengths in specific queries, suggesting that a hybrid approach may maximize utility. Meanwhile, the results for Gemini indicate potential for refinement to improve both consistency and empathy. By aligning model performance with the nature of clinical questions, healthcare professionals can better leverage AI tools for nephrology and other specialties, ensuring patient care and communication remain at the forefront. Future work should aim to optimize these models for both general clinical use and scenario-specific applications. 25
The consistency evaluation, subjectively assessed by nephrologists, was further validated using objective metrics such as TF-IDF, BertScore, and ROUGE, which revealed nuanced differences in the capabilities of the evaluated models. Given the complexity of explaining renal biopsy reports to patients compared to more direct-targeted questions, our focus shifted to this domain. Gemini 1.0 Ultra demonstrated notable strengths in summarizing intricate content, while GPT-4 excelled in accuracy and relevance, as evidenced by superior TF-IDF and BertScore results.
In our study, we employed a methodology where each nephrology-related question and renal biopsy report was submitted to the AI models three times consecutively. This approach was carefully chosen to assess the consistency and reliability of the responses generated by each model. Since LLMs operate as probabilistic systems, their responses can vary even when presented with the same input multiple times. By repeating each query three times, we aimed to detect any variability and evaluate the stability of the models’ outputs over repeated interactions. This aligns with existing research, such as the study by Shaier et al., 26 which examined the consistency of LLM-generated responses to health-related questions across different languages, highlighting the significance of repeated testing in understanding AI behavior. Beyond consistency, this three-repetition approach was selected as a practical and statistically meaningful strategy for evaluating AI performance. While larger sample sizes might offer more precision, repeating each query three times provides a balance between feasibility and statistical relevance. Prior research, such as Funk et al., 27 investigated ChatGPT's response consistency by administering medical examination questions three times, demonstrating that this approach effectively identifies inconsistencies while maintaining efficiency in data collection and analysis. In medical practice, the reliability of AI-generated responses is critical, particularly when AI is used to support physician–patient communication and patient education. If an AI system provides widely varying responses to identical queries, it raises concerns about its dependability in real-world clinical settings. The study by Yun et al. 28 examined AI's role in questionnaire-based interactions, emphasizing that maintaining consistency in AI-generated responses is essential for ensuring trust and reliability in healthcare applications. Our methodology allows us to determine whether AI-generated information remains stable across repeated interactions, ensuring that these models can serve as reliable tools in patient communication and medical education. Further, we asked repeated questions within the same session to allow the model to utilize in-context learning, as this approach more accurately reflects real-world clinical conditions. In actual medical practice, patients and physicians engage in continuous conversations where prior context influences subsequent discussions. By maintaining the same session, we aimed to assess the model's ability to adapt, retain relevant information, and provide contextually appropriate responses, simulating how AI might function as a supportive tool in clinical nephrology settings.
These findings underscore the unique strengths of each model. GPT-4 and GPT-4o stand out for their detailed and precise responses, making them suitable for scenarios requiring high accuracy. Gemini 1.0 Ultra is effective for generating coherent extended narratives, particularly for complex and nuanced topics like renal biopsy interpretation. PaLM 2, on the other hand, shows strength in keyword-focused and concise responses, making it effective for straightforward, targeted queries. This analysis highlights the importance of selecting AI models based on specific clinical demands to ensure optimal application and effectiveness in patient communication and care.
It's notable that all references provided by ChatGPT were verified as existing, contrasting with previous studies that cautioned against potential fake references generated by ChatGPT.29–32 Our study suggests improved reliability in GPT-4's references, which may be attributed to our IT engineer's effective prompting techniques. Future investigations could delve deeper into the relevance and accuracy of the references in relation to the provided information.
We observed that some responses generated by AI, which appeared relevant to Kidney-Related Queries, were mistakenly presented in the context of Renal Biopsy Reports. This phenomenon highlights the importance of having experienced clinicians supervise AI-generated content, as these responses can be a mix of fact and fiction, delivered with an air of authority. Additionally, while PaLM 2 scored relatively low across the categories of Appropriateness, Helpfulness, and Consistency as evaluated by experienced nephrologists, its empathy scores were notably higher, particularly in Q4 (91.67%) and Q15 (87.50%). However, PaLM 2's performance in terms of Appropriateness, Helpfulness, and Consistency for Q4 and Q8 did not align with its high empathy scores, pointing to a peculiar phenomenon: responses that are less accurate or inconsistent may still come across as empathetic and persuasive. This suggests that PaLM 2's inconsistency could reflect a manifestation of generative AI hallucinations, providing varied and sometimes incorrect answers to the same question. Such findings underscore the need for careful scrutiny of AI outputs, especially when addressing complex or sensitive clinical topics. Challenges like hallucinations, sycophancy, contextual misunderstandings, and limitations with complex numerical data reinforce the importance of human oversight and the integration of specialized systems. 33 Developing in-house or domain-specific models and aligning AI outputs with clinical guidelines can improve reliability. Future efforts should focus on enhancing contextual understanding and precision to optimize AI's role in clinical care.
We envisioned integrating generative AI into clinical nephrology practice as a supportive tool rather than a direct decision-making system. At the point of care, AI could assist in streamlining pre-consultation procedures by gathering patient histories, summarizing key concerns, and structuring responses for clinicians to review. This would enhance workflow efficiency by reducing administrative burdens and allowing physicians to focus on critical clinical decision-making. However, generative AI would not replace established clinical guidelines or protocols but rather complement existing procedures by improving patient engagement and comprehension.
Since we use generative AI as a supportive tool in clinical nephrology, its application is strictly limited to providing general knowledge for kidney disease patients, covering aspects such as dietary habits, important precautions, caregiving methods, and explanations of kidney biopsy data. These topics are widely recognized and standardized within Taiwan's nephrology practice, making them non-sensitive and generalizable, ensuring that no confidential patient information is involved in AI interactions.
We acknowledge concerns that data input into LLMs could be used beyond regulatory boundaries for model training. However, our study design minimizes this risk by restricting AI applications to non-personalized patient education rather than clinical decision-making. When explaining kidney biopsy data, the AI is only used to describe general pathological findings, such as common classifications of glomerular diseases, their clinical significance, and basic interpretations that align with nephrology textbooks and established guidelines. The AI does not process individual patient biopsy reports, ensuring that no sensitive medical records are exposed or stored externally.
Furthermore, compliance with hospital privacy policies and Taiwan's national healthcare regulations ensures that all AI interactions remain within ethical and legal boundaries. If future AI implementation expands to include patient-specific discussions, we will explore the use of on-premise AI models or privacy-enhanced AI solutions that prevent external data exposure. By structuring our study to focus strictly on general nephrology education, including kidney biopsy explanations, we effectively eliminate privacy risks while maximizing AI's benefits in patient communication and understanding.
If the study results are promising, we aim to implement AI in outpatient settings (general nephrology and dialysis units), where it could provide educational materials tailored to patients’ conditions, facilitate treatment adherence, and help triage common concerns before physician visits. Future integration would require institutional validation, regulatory oversight, and alignment with clinical nephrology protocols to ensure safety, accuracy, and ethical application in patient care.
Several limitations of this study should be acknowledged. First, the scoring was subjective, conducted by 16 experienced nephrologists and nephrology researchers from various regions and institutions across Taiwan, ranging from dialysis clinics to medical centers. These physicians also received fellowship training at diverse institutions. While the subjective evaluation aligns with the study's aim of assessing generative AI suitability for nephrology clinical settings, it reflects the perspectives of nephrologists rather than patients. This preliminary study excluded patient input, as responses that seem satisfactory to patients may not necessarily be accurate or clinically appropriate. Thus, the limitation of this study is the subjective nature of evaluating human-like empathy in generative AI responses. While the scoring was conducted by experienced nephrologists using a structured and standardized framework, the interpretation of empathy remains inherently subjective and may vary among evaluators. Additionally, the absence of objective metrics, such as linguistic or affective analysis, limits the ability to quantify empathy with greater precision. Future research should explore incorporating objective measures alongside expert evaluations to enhance the reliability and validity of empathy assessments in AI-generated responses. Second, this study is an initial evaluation and has not been tested in real-world clinical environments. Consequently, it does not address potential challenges that may arise when generative AI is applied in actual clinical settings. The lack of a comprehensive world model in AI systems further limits contextual appropriateness, emphasizing the need for ongoing improvements in contextual understanding. Third, the study's assumption that LLMs must be used warrants reconsideration. Alternatives, such as developing in-house models tailored to specific medical domains or enhancing existing LLMs with domain-specific training, may yield more reliable and customized solutions. Fourth, the use of a limited number of renal biopsy reports, focusing primarily on commonly encountered cases. While this approach was suitable for a preliminary evaluation of generative AI performance, it may not fully capture the variability and complexity of real-world renal biopsy scenarios. The lack of standardized analysis across a broader dataset of renal biopsies reports limits the generalizability of the findings. Future research should address these challenges, incorporating real-world testing, patient perspectives, and more robust methodologies, more sample size, more dialysis-related questions like “what do I need to pay attention to after dialysis” to optimize AI's role in nephrology clinical care. Regulatory compliance is another key factor. AI use must align with hospital policies, national regulations, and international standards (GDPR, HIPAA, WHO). Taiwan supports AI-driven medical advancements, allowing multicenter trials while enforcing data protection laws. Fifth, one limitation of this study is that the questionnaire used has not been formally validated. As this study is a pilot investigation, the primary aim was to explore preliminary findings rather than establish definitive conclusions. Although the questionnaire was developed based on relevant literature and expert consensus to ensure content validity, it has not undergone formal psychometric validation, such as reliability and validity testing. Future studies should consider conducting a structured validation process, including pilot testing with a larger sample, to ensure the robustness and generalizability of the findings. Finally, to
Conclusion
This study highlights the potential and limitations of generative AI models in nephrology clinical settings. While models like GPT-4 and GPT-4o demonstrated strengths in accuracy and relevance, and PaLM 2 showed notable empathy, inconsistencies and hallucinations underline the need for expert supervision. Subjective evaluations by experienced nephrologists provided valuable insights, but real-world testing and patient perspectives remain crucial for further validation. Our study explores generative AI in clinical nephrology, balancing its potential benefits and challenges. AI can enhance patient education, communication, and workflow efficiency, but must remain a supportive tool rather than a decision-maker. By assisting in gathering patient histories and summarizing key concerns, AI can streamline outpatient and dialysis care, allowing physicians to focus on complex cases while ensuring accuracy, safety, and ethical compliance.
LLMs are evolving at a continuous and rapid pace, and with their rapid development, integrating these constantly changing models into clinical practice presents a significant challenge. This study aims to evaluate the capabilities and performance of LLMs as a supportive bridge between patients and doctors, rather than as a decision-making tool. Since the focus is on facilitating communication and patient education, rather than clinical judgment, the findings remain relevant despite technological advancements. If the performance of the current LLMs in this study proves effective, it strongly suggests that future iterations, likely to be even more advanced and refined, will be even better suited for this supportive role in clinical practice.
Supplemental Material
sj-docx-1-dhj-10.1177_20552076251342067 - Supplemental material for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation
Supplemental material, sj-docx-1-dhj-10.1177_20552076251342067 for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation by Shih-Yi Lin, Chang-Cheng Jiang, Kin-Man Law, Pei-Chun Yeh, Min-Kuang Tsai, Chu-Lin Chou, I-Kuan Wang, I-Wen Ting, Yu-Wei Chen, Che-Yi Chou, Ming-Han Hsieh, Heng-Chih Pan, Sung-Lin Hsieh, Chien-Hua Chiu, Pei-Wen Lee, Yu-Cyuan Hong, Ying-Yu Hsu, Huey-Liang Kuo, Shu-Woei Ju and Chia-Hung Kao in DIGITAL HEALTH
Supplemental Material
sj-docx-2-dhj-10.1177_20552076251342067 - Supplemental material for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation
Supplemental material, sj-docx-2-dhj-10.1177_20552076251342067 for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation by Shih-Yi Lin, Chang-Cheng Jiang, Kin-Man Law, Pei-Chun Yeh, Min-Kuang Tsai, Chu-Lin Chou, I-Kuan Wang, I-Wen Ting, Yu-Wei Chen, Che-Yi Chou, Ming-Han Hsieh, Heng-Chih Pan, Sung-Lin Hsieh, Chien-Hua Chiu, Pei-Wen Lee, Yu-Cyuan Hong, Ying-Yu Hsu, Huey-Liang Kuo, Shu-Woei Ju and Chia-Hung Kao in DIGITAL HEALTH
Supplemental Material
sj-docx-3-dhj-10.1177_20552076251342067 - Supplemental material for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation
Supplemental material, sj-docx-3-dhj-10.1177_20552076251342067 for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation by Shih-Yi Lin, Chang-Cheng Jiang, Kin-Man Law, Pei-Chun Yeh, Min-Kuang Tsai, Chu-Lin Chou, I-Kuan Wang, I-Wen Ting, Yu-Wei Chen, Che-Yi Chou, Ming-Han Hsieh, Heng-Chih Pan, Sung-Lin Hsieh, Chien-Hua Chiu, Pei-Wen Lee, Yu-Cyuan Hong, Ying-Yu Hsu, Huey-Liang Kuo, Shu-Woei Ju and Chia-Hung Kao in DIGITAL HEALTH
Supplemental Material
sj-docx-4-dhj-10.1177_20552076251342067 - Supplemental material for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation
Supplemental material, sj-docx-4-dhj-10.1177_20552076251342067 for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation by Shih-Yi Lin, Chang-Cheng Jiang, Kin-Man Law, Pei-Chun Yeh, Min-Kuang Tsai, Chu-Lin Chou, I-Kuan Wang, I-Wen Ting, Yu-Wei Chen, Che-Yi Chou, Ming-Han Hsieh, Heng-Chih Pan, Sung-Lin Hsieh, Chien-Hua Chiu, Pei-Wen Lee, Yu-Cyuan Hong, Ying-Yu Hsu, Huey-Liang Kuo, Shu-Woei Ju and Chia-Hung Kao in DIGITAL HEALTH
Supplemental Material
sj-docx-5-dhj-10.1177_20552076251342067 - Supplemental material for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation
Supplemental material, sj-docx-5-dhj-10.1177_20552076251342067 for Evaluation of generative AI assistance in clinical nephrology: Assessing GPT-4, GPT-4o, Gemini 1.0 Ultra, and PaLM 2 in patient interaction and renal biopsy interpretation by Shih-Yi Lin, Chang-Cheng Jiang, Kin-Man Law, Pei-Chun Yeh, Min-Kuang Tsai, Chu-Lin Chou, I-Kuan Wang, I-Wen Ting, Yu-Wei Chen, Che-Yi Chou, Ming-Han Hsieh, Heng-Chih Pan, Sung-Lin Hsieh, Chien-Hua Chiu, Pei-Wen Lee, Yu-Cyuan Hong, Ying-Yu Hsu, Huey-Liang Kuo, Shu-Woei Ju and Chia-Hung Kao in DIGITAL HEALTH
Footnotes
Author contributions
Conceptualization, methodology, project administration, and supervision were done by S.-Y. L. and C.-H. K. Data curation and investigation were done by S.-Y. L.; C.-C. J.; K.-M. L.; P.-C. Y.; H.-L. K.; S.-W. J. Formal analysis was accomplished by K.-M. L.; P.-C. Y. Software was provided by K.-M. L.; P.-C. Y. Writing—original draft, reviewing, and editing were done by all authors.
Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Data availability statement
The datasets generated and analyzed during this study, including the responses from AI platforms (GPT-4, GPT-4o, Gemini 1.0 Ultra, PaLM 2) to nephrology-related questions and renal biopsy report interpretations, are not publicly available due to ethical and privacy considerations. These considerations pertain to the protection of proprietary information inherent in the AI platforms’ responses and the sensitivity of medical data. This study did not involve human or animal subjects, and thus, no ethical approval was required. The study protocol adhered to the guidelines established by the journal. The protocol was also under the premise of safeguarding the confidentiality and integrity of the proprietary AI methodologies and ensuring the privacy of hypothetical patient data embedded in the biopsy reports.
For researchers interested in accessing the data within the constraints of these ethical considerations, requests can be made to the corresponding author. Upon request, and where feasible, the research team is prepared to provide summaries of the AI responses and statistical analyses performed.
For further inquiries or requests for data access, please contact the corresponding author via mail.
Presentation
Will be presented as a poster at the Internal Medicine and Nephrology Annual Meeting.
Supplemental material
Supplemental material for this article is available online.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
